Overview of the immune biology of allogeneic hematopoietic stem cell transplantation - Immune Biology of Allogeneic Hematopoietic Stem Cell Transplantation - page 14

[29] Teshima T, Ordemann R, Reddy P, Gagin S, Liu C, Cooke KR, et al. Acute graft-versus-
host disease does not require alloantigen expression on host epithelium. Nat Med
2002;8(6):575-81.
[30] Zhang Y, Joe G, Hexner E, Zhu J, Emerson SG. Host-reactive CD8 + memory stem cells in
graft-versus-host disease. Nat Med 2005;11(12):1299-305.
[31] Ferrara J. Location, location, location. Nat Immunol 2003;4(2):103-4.
[32] Hadeiba H, Sato T, Habtezion A, Oderup C, Pan J, Butcher EC. CCR9 expression defines
tolerogenic plasmacytoid dendritic cells able to suppress acute graft-versus-host
disease. Nat Immunol 2008;9(11):1253-60.
[33] Jones SC, Murphy GF, Friedman TM, Korngold R. Importance of minor histocompat-
ibility antigen expression by nonhematopoietic tissues in a CD4 + T cell-mediated
graft-versus-host disease model. J Clin Invest 2003;112(12):1880-6.
[34] Matte CC, Liu J, Cormier J, Anderson BE, Athanasiadis I, Jain D, et al. Donor APCs are
required for maximal GVHD but not for GVL. Nat Med 2004;10(9):987-92.
[35] Murai M, Yoneyama H, Ezaki T, Suematsu M, Terashima Y, Harada A, et al. Peyer's patch
is the essential site in initiating murine acute and lethal graft-versus-host reaction. Nat
Immunol 2003;4(2):154-60.
[36] Ordemann R, Hutchinson R, Friedman J, Burakoff SJ, Reddy P, Duffner U, et al.
Enhanced allostimulatory activity of host antigen-presenting cells in old mice intensi-
fies acute graft-versus-host disease. J Clin Invest 2002;109(9):1249-56.
[37] Shlomchik WD, Couzens MS, Tang CB, McNiff J, Robert ME, Liu J, et al. Prevention
of graft versus host disease by inactivation of host antigen-presenting cells. Science
1999;285(5426):412-15.
[38] Zhang Y, Louboutin JP, Zhu J, Rivera AJ, Emerson SG. Preterminal host dendritic cells
in irradiated mice prime CD8 + T cell-mediated acute graft-versus-host disease. J Clin
Invest 2002;109(10):1335-44.
[39] Lee SJ, Klein J, Haagenson M, Baxter-Lowe LA, Confer DL, Eapen M, et al. High-reso-
lution donor-recipient HLA matching contributes to the success of unrelated donor
marrow transplantation. Blood 2007;110(13):4576-83.
[40] Goulmy E, Gratama JW, Blokland E, Zwaan FE, van Rood JJ. A minor transplantation
antigen detected by MHC-restricted cytotoxic T lymphocytes during graft-versus-host
disease. Nature 1983;302(5904):159-61.
[41] Kamei M, Nannya Y, Torikai H, Kawase T, Taura K, Inamoto Y, et al. HapMap scanning
of novel human minor histocompatibility antigens. Blood 2009;113(21):5041-8.
[42] Mutis T, Gillespie G, Schrama E, Falkenburg JH, Moss P, Goulmy E. Tetrameric HLA
class I-minor histocompatibility antigen peptide complexes demonstrate minor histo-
compatibility antigen-specific cytotoxic T lymphocytes in patients with graft-versus-
host disease. Nat Med 1999;5(7):839-42.
[43] Choi EY, Christianson GJ, Yoshimura Y, Sproule TJ, Jung N, Joyce S, et al. Immunodomi-
nance of H60 is caused by an abnormally high precursor T cell pool directed against its
unique minor histocompatibility antigen peptide. Immunity 2002;17(5):593-603.
[44] Fontaine P, Roy-Proulx G, Knafo L, Baron C, Roy DC, Perreault C. Adoptive transfer of
minor histocompatibility antigen-specific T lymphocytes eradicates leukemia cells
without causing graft-versus-host disease. Nat Med 2001;7(7):789-94.
[45] Collin MP, Hart DN, Jackson GH, Cook G, Cavet J, Mackinnon S, et al. The fate of
human Langerhans cells in hematopoietic stem cell transplantation. J Exp Med
2006;203(1):27-33.
[46] Ginhoux F, Collin MP, Bogunovic M, Abel M, Leboeuf M, Helft J, et al. Blood-derived
dermal langerin + dendritic cells survey the skin in the steady state. J Exp Med
2007;204(13):3133-46.
[47] Haniffa M, Ginhoux F, Wang XN, Bigley V, Abel M, Dimmick I, et al. Differential rates of
replacement of human dermal dendritic cells and macrophages during hematopoietic
stem cell transplantation. J Exp Med 2009;206(2):371-85.
[48] Dickinson AM, Holler E. Polymorphisms of cytokine and innate immunity genes and
GVHD. Best Pract Res Clin Haematol 2008;21(2):149-64.
[49] Holler E, Rogler G, Brenmoehl J, Hahn J, Herfarth H, Greinix H, et al. Prognostic
significance of NOD2/CARD15 variants in HLA-identical sibling hematopoietic stem
cell transplantation: effect on long-term outcome is confirmed in 2 independent
cohorts and may be modulated by the type of gastrointestinal decontamination. Blood
2006;107(10):4189-93.
[50] She K, Gilman AL, Aslanian S, Shimizu H, Krailo M, Chen Z, et al. Altered Toll-like
receptor 9 responses in circulating B cells at the onset of extensive chronic graft-versus-
host disease. Biol Blood Marrow Transplant 2007;13(4):386-97.

14